PRQR Overview

Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.

Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.

General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.

Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.

Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

ProQR's Clinical Trial Approval: ProQR Therapeutics has received authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 clinical trial of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP, aimed at treating cholestatic diseases.

Upcoming Investor Event: ProQR will host a virtual event on November 3, 2025, to discuss the safety, pharmacokinetics, and biomarker roadmap for AX-0810, featuring presentations from ProQR management and Professor Henkjan J. Verkade, a key opinion leader in pediatric gastroenterology.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

ProQR Therapeutics Phase 1 Trial Announcement: ProQR Therapeutics has submitted a Clinical Trial Application to the European Medicines Agency for its investigational drug AX-0810, targeting cholestatic liver diseases by modulating the NTCP protein, with initial safety and engagement data expected by Q4 2025.

Axiomer RNA Editing Technology: The trial represents a significant milestone for ProQR as it advances its Axiomer RNA editing platform into clinical development, aiming to address the unmet medical needs in cholestatic liver disease through innovative therapeutic approaches.